Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Prilosec OTC Claims Found False; P&G Appeals Federal Court Ruling

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Procter & Gamble says the impact of a Sept. 19 court-ordered preliminary injunction against the use of its "one pill, 24 hours, zero heartburn" claim for Prilosec OTC will be "trivial" and immaterial to the product launch

You may also be interested in...



Mylan Seeks Halt Of “Misleading” Prilosec OTC Ad Claims In Suit

Mylan Labs requests preliminary and permanent injunctions against Procter & Gamble ad claims that Prilosec OTC and Rx Prilosec are the same drug in its complaint against the firm in Manhattan federal court

Mylan Seeks Halt Of “Misleading” Prilosec OTC Ad Claims In Suit

Mylan Labs requests preliminary and permanent injunctions against Procter & Gamble ad claims that Prilosec OTC and Rx Prilosec are the same drug in its complaint against the firm in Manhattan federal court

Mylan Seeks Halt Of “Misleading” Prilosec OTC Ad Claims In Suit

Mylan Labs requests preliminary and permanent injunctions against Procter & Gamble ad claims that Prilosec OTC and Rx Prilosec are the same drug in its complaint against the firm in Manhattan federal court

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS095990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By